---
document_datetime: 2024-10-21 15:46:49
document_pages: 18
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/tepadina-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: tepadina-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 9.9256605
conversion_datetime: 2025-12-28 10:03:06.825308
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## TEPADINA

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                         | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| II/0050/G            | This was an application for a group of variations. B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place | 13/06/2024                          |                                             | SmPC, Labelling and PL           |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|           | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.1.z - Replacement or addition of a manufacturing site for the FP - Other variation B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier B.II.e.z - Change in container closure system of the Finished Product - Other variation B.II.d.1.e - Change in the specification parameters and/or limits of the finished product - Change outside the approved specifications limits range B.II.f.1.b.3 - Stability of FP - Extension of the shelf life of the finished product - After dilution or   |            |            |                        | reconstitution   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|------------------|
| X/0049    | Annex I_2.(c) Change or addition of a new strength/potency                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 25/01/2024 | 21/03/2024 | SmPC, Labelling and PL |                  |
| IB/0051/G | This was an application for a group of variations. B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data) B.II.f.1.b.1 - Stability of FP - Extension of the shelf the finished product - As packaged for sale                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 29/02/2024 |            | SmPC                   | life of          |

<div style=\"page-break-after: always\"></div>

|           | (supported by real time data)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |            |            |                        |                                                                                                                                                                                                        |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0048   | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                                                                                                                                                                                               | 12/06/2023 | n/a        |                        |                                                                                                                                                                                                        |
| II/0046/G | This was an application for a group of variations. B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.1.z - Replacement or addition of a manufacturing site for the FP - Other variation B.II.e.4.c - Change in shape or dimensions of the container or closure (immediate packaging) - Sterile medicinal products B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect | 30/03/2023 | n/a        |                        |                                                                                                                                                                                                        |
| IB/0047   | B.II.f.1.b.3 - Stability of FP - Extension of the shelf life of the finished product - After dilution or reconstitution (supported by real time data)                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 28/03/2023 | 21/03/2024 | SmPC, Labelling and PL |                                                                                                                                                                                                        |
| IB/0044   | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 05/01/2022 | 08/07/2022 | SmPC and PL            | To update the shelf life of Tepadina 400mg from '18 months' to '24 months' in section 6.3 of the Summary of Product Characteristics (SmPC). To update the list of local representatives in the package |

<div style=\"page-break-after: always\"></div>

|                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |            |     | leaflets.                         |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| IB/0043/G          | This was an application for a group of variations. B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer | 09/12/2021 | n/a |                                   |
| PSUSA/2932/ 202103 | Periodic Safety Update EU Single assessment - thiotepa                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 02/12/2021 | n/a | PRAC Recommendation - maintenance |
| IB/0042/G          | This was an application for a group of variations. B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation                                                                                                                                                                                                                                   | 06/09/2021 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

| IB/0040   | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 05/08/2021   | 08/07/2022   | SmPC, Labelling and PL   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------------------------|
| X/0036    | Annex I_2.(c) Change or addition of a new strength/potency Annex I_2.(d) Change or addition of a new pharmaceutical form                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 28/01/2021   | 26/03/2021   | SmPC, Labelling and PL   |
| IB/0039/G | This was an application for a group of variations. B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.c.1.z - Change in immediate packaging of the AS - Other variation A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder | 20/11/2020   | n/a          |                          |

<div style=\"page-break-after: always\"></div>

|           | intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |            |            |                       |                     |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|---------------------|
| IB/0038/G | This was an application for a group of variations. B.II.e.2.z - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Other variation B.II.e.2.c - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) B.II.e.2.c - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) B.II.e.2.c - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure A.7 - Administrative change - Deletion of | 03/11/2020 | 26/03/2021 | SmPC, Annex II and PL | manufacturing sites |
| N/0037    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 14/01/2020 | 03/11/2020 | PL                    |                     |

<div style=\"page-break-after: always\"></div>

| II/0034   | - Change in the manufacturer of AS or of a material/reagent/intermediate for AS - of a manufacturer of the AS supported an ASMF                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 12/12/2019   | n/a        |                       | B.I.a.1.b starting Introduction by   |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------------|--------------------------------------|
| II/0035/G | This was an application for a group of variations. B.II.b.1.z - Replacement or addition of a manufacturing site for the FP - Other variation B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing B.II.e.1.z - Change in immediate packaging of the | 14/11/2019   | 03/11/2020 | SmPC, Annex II and PL | finished product - Other             |
| N/0033    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 11/06/2019   | 03/11/2020 | PL                    |                                      |
| IA/0032/G | This was an application for a group of variations. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 20/12/2018   | n/a        |                       |                                      |

<div style=\"page-break-after: always\"></div>

|                    | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure   |            |            |                 |                                   |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|-----------------------------------|
| PSUSA/2932/ 201803 | Periodic Safety Update EU Single assessment - thiotepa                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 31/10/2018 | n/a        |                 | PRAC Recommendation - maintenance |
| IAIN/0030/G        | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) B.II.b.2.c.2 - Change to importer, batch release arrangements and quality control testing of the FP - Including batch control/testing B.II.b.5.a - Change to in-process tests or limits                                                                                                                                                                                                                                                                                                                                                            | 29/11/2017 | 02/08/2018 | Annex II and PL |                                   |

<div style=\"page-break-after: always\"></div>

|           | during the manufacture of the finished - Tightening of in-process limits                                                                                                                                                                                                                                                                                                                                       |            |            |                                  | applied product   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-------------------|
| IB/0029   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                 | 15/08/2017 | 02/08/2018 | SmPC, Annex II, Labelling and PL |                   |
| IA/0028/G | This was an application for a group of variations. B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product - Addition of a new test(s) and limits                                                                        | 05/12/2016 | n/a        |                                  |                   |
| N/0027    | Update of the package leaflet with revised contact details of the local representative for France. Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                            | 12/04/2016 | 12/05/2016 | PL                               |                   |
| II/0026   | Update of section 4.8 of the SmPC in order to update the safety information on leukoencephalopathy. The Package Leaflet is updated accordingly. In addition, the Marketing authorisation holder (MAH) took the opportunity to make editorial changes in the PI. C.I.3.b - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the | 25/02/2016 | 12/05/2016 | SmPC and PL                      | assessment done   |

<div style=\"page-break-after: always\"></div>

|                    | new additional data submitted by the MAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |            |     |                                   |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| PSUSA/2932/ 201503 | Periodic Safety Update EU Single assessment - thiotepa                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 06/11/2015 | n/a | PRAC Recommendation - maintenance |
| II/0025/G          | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site B.II.b.1.f - Replacement or addition of a manufacturing site for part or all of the manufacturing process of the FP - Site where any manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for sterile medicinal products (including those that are aseptically manufactured) excluding biological/ immunological medicinal products B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process | 05/11/2015 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

|         | size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size B.II.b.4.b - Change in the batch size (including batch size ranges) of the finished product - Downscaling down to 10-fold B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product - Addition of a new test(s) and limits B.II.b.5.c - Change to in-process tests or limits applied during the manufacture of the finished product - Deletion of a non-significant in-process test B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.e.1.a.3 - Change in immediate packaging of the finished product - Qualitative and quantitative composition - Sterile medicinal products and biological/immunological medicinal products B.II.e.4.c - Change in shape or dimensions of the container or closure (immediate packaging) - Sterile   |            |            |             |     |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----|
| II/0021 | Update of section 4.8 of the SmPC to add the ADR 'severe toxic skin reactions including cases of Stevens-Johnson syndrome and toxic epidermal necrolysis' with unknown frequency. The Package Leaflet has been updated accordingly. In addition, the MAH took the opportunity to update the contact details for the local representatives in Greece and                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 24/09/2015 | 12/05/2016 | SmPC and PL | N/A |

<div style=\"page-break-after: always\"></div>

|           | Cyprus in the Package Leaflet. A revised RMP version 12 was agreed during the procedure. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                 |            |            |                        |                                                                                                                                                                                                      |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0023   | B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size                                                                                                                                                                                                                                                                                                                                                                                               | 16/07/2015 | n/a        |                        |                                                                                                                                                                                                      |
| IA/0022/G | This was an application for a group of variations. B.II.d.1.d - Change in the specification parameters and/or limits of the finished product - Deletion of a non-significant specification parameter B.II.d.1.d - Change in the specification parameters and/or limits of the finished product - Deletion of a non-significant specification parameter                                                                                                                                                                                                     | 06/07/2015 | n/a        |                        |                                                                                                                                                                                                      |
| II/0018   | Update of section 4.8 of the SmPC in order to add pulmonary arterial hypertension as a new adverse drug reaction (ADR) with unknown frequency in the paediatric population. The Package Leaflet and the RMP (version 11.0) are updated accordingly. The MAH also took the opportunity to make some editorial changes according to the QRD template, to align the package leaflet between strengths and to update the local representative information for Croatia in the Package Leaflet. In addition, a minor change was introduced in the address of the | 21/05/2015 | 12/05/2016 | SmPC, Labelling and PL | Pulmonary Arterial hypertension is added as an adverse drug reaction to the Tepadina product information after analysis of worldwide post-marketing experience, clinical- trial data and literature. |

<div style=\"page-break-after: always\"></div>

|           | Marketing Authorisation Holder as agreed with the Agency. A revised RMP (version 11.0) is agreed including the new important potential risk of pulmonary arterial hypertension. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation   |            |            |                        |                                                                                                                                                                                                                                                                                                                                                                                                 |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0019   | B.II.d.1.g - Change in the specification parameters and/or limits of the finished product - Addition or replacement (excluding biological or immunological product) of a specification parameter wit its corresponding test method as a result of a safety or quality issue      | 11/04/2015 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                 |
| IAIN/0020 | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                  | 16/03/2015 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                 |
| R/0017    | Renewal of the marketing authorisation.                                                                                                                                                                                                                                          | 25/09/2014 | 17/11/2014 | SmPC, Labelling and PL | Based on the review of the available information, the CHMP is of the opinion that the quality, the safety and the efficacy of this medicinal product continues to be adequately and sufficiently demonstrated and therefore considers the benefit/risk profile of Tepadina continues to be favourable. The CHMP is also of the opinion that the renewal can be granted with unlimited validity. |
| N/0016    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                 | 06/06/2014 | 17/11/2014 | PL                     |                                                                                                                                                                                                                                                                                                                                                                                                 |
| IAIN/0015 | B.II.b.1.a - Replacement or addition of a                                                                                                                                                                                                                                        | 19/05/2014 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

|             | site for the FP - Secondary packaging                                                                                                                                                                                                                                                                                                                                                                                      |            |            |                                  | manufacturing site                      |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-----------------------------------------|
| IAIN/0014   | Infertility is an adverse drug reaction of chemotherapeutic regimens employing Tepadina which occurs at a frequency 'common' (affects up to 1 to 10 people)'. C.I.3.a - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Implementation of competent authority                                         | 21/02/2014 | 28/04/2014 | SmPC, Annex II, Labelling and PL | wording agreed by the                   |
| IAIN/0013/G | was an application for a group of variations. - Administrative change - Change in the name address of the MAH - Administrative change - Deletion of                                                                                                                                                                                                                                                                        | 18/10/2013 | 28/04/2014 | SmPC, Labelling and PL           | This A.1 and/or A.7 manufacturing sites |
| IAIN/0012/G | This was an application for a group of variations. C.I.9.a - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the QPPV C.I.9.b - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the contact details of the QPPV C.I.9.c - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the back-up procedure of the QPPV | 05/08/2013 | n/a        |                                  |                                         |

<div style=\"page-break-after: always\"></div>

|             | C.I.9.g - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the site undertaking pharmacovigilance activities C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system                          |            |            |                 |                                  |
|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|----------------------------------|
| II/0010/G   | application for a group of variations. Change to the method and specification for the parameter clarity of solution. B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.1.e - Change in the specification parameters and/or limits of the finished product - Change specifications limits range | 25/04/2013 | 25/04/2013 | SmPC and PL     | This was an outside the approved |
| IAIN/0011/G | This was an application for a group of variations. A.5.a - Administrative change - Change in the name and/or address of a manufacturer responsible for batch release B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of limits                                                    | 15/04/2013 | 28/04/2014 | Annex II and PL | specification                    |
| IAIN/0009/G | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                               | 31/08/2012 | n/a        |                 |                                  |

<div style=\"page-break-after: always\"></div>

|           | C.I.9.a - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the QPPV C.I.9.c - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the back-up procedure of the QPPV C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system   |            |            |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0008   | B.II.b.2.a - Change to batch release arrangements and quality control testing of the FP - Replacement or addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                               | 01/06/2012 | n/a        |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| N/0006    | Update of the Greek local representative contact details and deletion of duplicate information in the Spanish package leaflet. Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                   | 24/01/2012 | 28/04/2014 | PL                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| II/0004/G | This was an application for a group of variations. This was an application for a group of variations. Update of sections 4.2 and 6.6 of the SmPC regarding reconstitution instructions and final target concentration in the solution for infusion and update of section 6.3 of the SmPC to amend shelf life. The PL was updated accordingly and additional changes were made to bring the PL in line with the SmPC.              | 21/07/2011 | 26/08/2011 | SmPC, Annex II and PL | Each 15 mg Tepadina vial must be reconstituted with 1.5 ml of sterile water for injection (10 ml for each 100 mg vial). The total volume of reconstituted vials to be administered should be further diluted in 500 ml of sodium chloride 9 mg/ml (0.9%) solution for injection prior to administration (1000 ml if the dose is higher than 500 mg). In children, if the dose is lower than 250 mg, an appropriate volume of sodium chloride 9 mg/ml (0.9%) solution for injection may be used in order to obtain a final |

<div style=\"page-break-after: always\"></div>

|           | The version number of the Pharmacovigilance System was deleted from Annex II, a mistake was corrected in section 4.2 of the SmPC and in the PL, the list of local representatives in the PL was updated and additional changes were made to the PI in accordance with the latest version of the QRD template (v 7.3.1 March 2010) C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data B.II.f.1.b.3 - Stability of FP - Extension of the shelf life of the finished product - After dilution or reconstitution (supported by real time data)   |            |     | TEPADINA concentration between 0.5 and 1 mg/ml. Chemical and physical in use stability of Tepadina after dilution has been demonstrated for 24 hours when stored at 2 8C and for 4 hours when stored at 25C.   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0005/G | This was an application for a group of variations. B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an ASMF B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an ASMF B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an ASMF B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an ASMF B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of             | 03/05/2011 | n/a |                                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

|           | B.III.2.b - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State                                                                                                                                                                                                      |            |     |          | specification limits   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----------|------------------------|
| N/0002    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                           | 17/03/2011 | n/a | PL       |                        |
| IA/0001/G | This was an application for a group of variations. C.I.9.a - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the QPPV C.I.9.b - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the contact details of the QPPV C.I.9.c - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the back-up procedure of the QPPV | 21/05/2010 | n/a | Annex II |                        |